Purpose To evaluate choriocapillaris (CC) and choroidal vascular changes in patients with posterior uveitis using swept-source (SS) wide-field optical coherence tomography angiography (OCTA).
Method Consecutive patients with posterior uveitis were evaluated using 3×3 mm and 12×12 mm OCTA scan patterns and montage images of 5×12×12 mm or 2×15×9 mm, covering approximately 70°–90° of the retina. The images were quantitatively and qualitatively analysed and compared with healthy controls.
Results Eighty-six eyes of 56 patients with posterior uveitis (mean age 45.2±19.9 years; 58.9% female), and 38 eyes of 19 age-matched healthy controls (57.9% female) were included. The mean perfusion density (PD) in 3×3 mm and 12×12 mm CC scans was significantly lower in eyes with posterior uveitis compared with those of healthy controls. However, no significant difference in the mean PD of choroidal scans was found comparing eyes with posterior uveitis and healthy controls. The mean PD in eyes with active disease was significantly higher compared with the inactive eyes on 12×12 mm choroidal scans (55.61% vs 51.25%, p=0.02), while no difference was found in the CC slabs.
Conclusion CC and choroidal assessment using OCTA provides useful information in patients with posterior uveitis. SS-OCTA metrics of the CC and choroidal slabs are promising tools in uveitis patients in the future.
Trial registration number NCT02811536.
Data availability statement
Data are available on reasonable request.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors MT: data acquisition, data analysis, drafting the manuscript. GZ: data analysis, revising manuscript for important intellectual content. MZ: data acquisition, revising manuscript for important intellectual content CT: data acquisition, revising manuscript for important intellectual content. SW: data acquisition, revising manuscript for important intellectual content. MRM: conception of work, data acquisition, data analysis, revising manuscript for important intellectual content.
Funding MRM: Consultant: Novartis, Zeiss, Gensight biologics, Lumithera, Lecturer fees and travel support: Bayer. Sebastian Wolf: Consultant: Novartis, Zeiss, Heidelberg, Bayer. MZ: Consultant: Novartis, Heidelberg, Bayer, Stocks: CT: none.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.